Summary. Investigation of the subcellular and molecular components of insulin secretion has been made difficult by the small quantities of material available. The recent development of a transplantable rat islet cell tumour of high insulin content and state of differentiation suggested a system more amenable to analysis. To validate the tumour as a model of secretion we have studied its release of insulin. In acute experiments in vitro immunoreactive insulin release was increased by leucine, glucagon, theophylline and dibutyryl cyclic AMP, though not by glucose. Leucine (20 mmol/1) plus theophylline (5 mmol/1) caused an abrupt, sustained and rapidly reversible stimulation of two-to fivefold. The response was inhibited by antagonists of cellular oxidative phosphorylation (cyanide, 2,4--dinitrophenol, antimycin A), calcium flux (EGTA, verapamil, Mg2 § calmodulin (trifluoperazine), microtubules (vinblastine, colchicine) and by adrenaline and somatostatin. These findings suggest that the tumour secretes insulin by an exocytotic mechanism similar to that of normal islet tissue.
The pancreatic B cell has proved difficult to investigate at the subcellular and molecular levels. The classical strategy of subcellular fractionation, purification and reassembly has been greatly hindered by the shortage of starting material [3, 4] . In this context the description recently of a transplantable rat islet cell tumour is of considerable interest. The tumour contains large amounts of insulin and consists predominantly of well-granulated cells the morphology of which closely resembles that of rat B cells [1, 2] .
That this islet cell tumour might offer a largescale model of insulin secretion is an attractive possibility. Realisation of this potential, however, depends upon establishing that the tumour is indeed capable of the exocytosis of insulin. We here report a series of experiments in which the characteristics of insulin release by the turnout were defined. The effect of putative secretagogues, the dynamics of insulin release, and the influence of potentiators and inhibitors of secretion are described.
Materials and Methods
The islet cell tumour [1, 2] was maintained by serial subcutaneous transplantation within a colony of inbred albino NEDH strain rats [2] .
Buffers
Tissue was handled in a Krebs Ringer solution [5] containing NaC1 115mmol/1, KC1 5.0mmol/1, NaI-ICO 3 24mmol/1, MgC12 1.0 mmol/1 and CaC12 2.5 mmol/1, freshly equilibrated with 5% CO 2 95% 02. Except where specified glucose 2.8 mmol/l, bovine plasma albumin (Armour Pharmaceuticals, Eastbourne, UK) 1.0 mg/ml, and 5.0 mmol/1 each of sodium pyruvate, monosodium glutamate and disodium fumarate were included (using 95 mmol/l NaC1 to maintain the final sodium ion concentration at 139 mmol/ 1). When individual experiments required further additions the osmolality of control buffers was balanced using sucrose.
Chemicals were purchased from Fisons Scientific Apparatus, Loughborough, UK and British Drug House Chemicals, Poole, UK, and were of the highest purity available.
Incubations
Tumours were speedily excised and placed in ice-cold buffer. For perifusion studies tumour was finely divided with scissors, washed once, and preincubated in a 37 ~ water bath for 45 min. Fragments were transferred to a chamber containing a 25 mm diameter 5 btm porosity polycarbonate filter (Nuclepore Corporation, Pleasanton, USA) and the chamber, inserted in line with a peristaltic pump delivering buffer at 2 ml/min, replaced in the water bath. Due to high initial backgrotmd release of insulin a stabilization period of 105 rain preceded any experiment. For static incubation studies tumour cells were suspended by repeatedly expelling turnout fragments from a Pasteur pipette. Connective tissue was removed by filtering through nylon mesh. After washing four times (centrifuging at 600 g) the cells were resuspended in a siliconised glass tube containing 20 ml of buffer, and placed in a 37 ~ water bath. Four consecutive 60 min incubations followed, with hourly resuspension in fresh buffer, to allow background insulin release to stabilise. During the first hour 10% of tissue insulin was released into the supernatant, compared with 2-3% in the fourth. The cells were washed. Viewed by phase contrast microscopy the suspension contained turnout cells singly and in small clusters, accompanied by an occasional red blood cell. For counting, a sample of cells was disaggregated using 5 mmol/1 EGTA: 60-80% of cells excluded trypan blue. The cells were aliquoted into capped plastic tubes (No. 72.690 from Walter Sarstedt (UK), Leicester, UK), washed, and resuspended each in 1.0 ml of buffers containing the various test substances. The tubes were placed in glass vials which, after flushing with 5% CO 2 95% 02 and capping, were returned to the 37 ~ water bath. On completing the final 60 min incubation the tubes were centrifuged (4 min at 600 g, 1 rain at 3000 g) and the snpernatants and pellets separated.
After each experiment residual tissue insulin was extracted overnight at 4 ~ using a mixture 50 : 16 : 1 by volume of absolute ethanol:water: 1.18 sp. gr. HC1. Immunoreactive insulin was determined [6] using guinea-pig antibovine insulin serum raised locally, and 125I-insulin from the Radiochemical Centre, Amersham, UK, or prepared from bovine insulin (Sigma, Poole, UK) by the iodogen method [7] .
Secretagogues and Inhibitors
Antimycin A was purchased from Boehringer (London), Lewes, UK, verapamil was obtained as Cordilox from Abbot Laboratories Queenborough, UK, and trifluoperazine dihydrochloride was the gift of Smith Kline & French Laboratories, Welwyn Garden City, UK. Other agents were purchased from British Drug House or Sigma. All were introduced in the final incubation buffer except verapamil, which was ineluded in the preceding wash, and vinblastine and colchicine, each of which was also present during the final hour of preincubation.
Data Presentation
Between individual experiments there were variations both in basal release of insulin and in the additional release induced by secretagogues. To allow comparison and pooling of data from static experiments investigating different inhibitors, insulin release was expressed relative to the increment in insulin release induced in each experiment by the stimulus of leucine (20 ram01/!) plus theophylline (5 mmol/1); using the following ratio:
[(release in presence of inhibitor) -(basal release)]/ [(release in presence of stimulus alone) -(basal release)]
Basal insulin release was that release in the absence either of stimulus or inhibitor.
For similar reasons, and to aid comparison with the static incubation experiments, insulin released during each minute of perifusion was expressed as a rate:
(insulin in minute fraction/insulin content of turnour fragments) • 6,000 = percentage tissue insulin content released per hour Significance of differences was calculated using Student's t test for unpaired data.
Results

Secretagogues
In acute experiments no response by the islet ceil tumour to glucose was detected. Stimulation was attempted using glucose concentrations of 8.4 to 48mmol/1, from a baseline of either zero or 2.8 mmol/1 glucose, and in both the presence and absence of 5 mmol/1 theophylline. Preincubation neither with 28mmol/1 glucose plus 20mmol/1 leucine for 60 min, nor with 48 mmol/1 glucose for 30 min conferred sensitivity to the subsequent presentation of glucose.
In contrast, increased release of insulin was provoked by leucine and by theophylline. Maximum response to leucine was obtained using 20 mmol/1 and to theophylline using 5 mmol/1. The typical effect of these concentrations in perifusion and static incubation experiments is illustrated in Figure 1 and Release of insulin from the tumour was also induced by dibutyryl cyclic AMP, the effect of (12) a Significant difference from release induced by leucine/theophylline in the same experiment (p < 0.01) b Significant difference from release induced by leucine/theophylline in the same experiment (t7 < 0.001) Table 1 . The dose-dependent stimulation by glucagon of insulin release is shown in Table 2 .
In the above experiments buffers were supplemented with 2.8 mmol/1 glucose and 5.0 mmol/1 each of pyruvate, glutamate and fumarate. The dependence on this supplementation of the responses to leucine and theophylline was examined. Following 227 the usual preincubation and perifusion run-in using supplemented buffer, a buffer lacking these additions was substituted. After exposure to this unsupplemented buffer for either 15 or 60 min theophylline and leucine were individually introduced. Each caused brisk increases in insulin release comparable to those previously obtained; baseline change was seen neither on substitution with simple buffer nor on reversion to the supplemented buffer. Table 3 . To allow comparison of data from different experiments results are expressed relative to the increase in insulin release induced by leucine plus theophylline in each experiment (as described under Methods).
The calcium dependency of stimulated insulin release was explored by omitting calcium chloride from the buffer, sodium EGTA (1.0 mmol/1) being added to chelate residual calcium ions. Alternatively, the addition to calcium-containing buffer of either verapamil (101xmol/l) or magnesium chloride (10 mmol/1) was tested. In all instances a reduction in insulin release was obtained (Table 4) . In data not shown, the presence of lanthanum chloride (3 mmol/1) or cobaltous chloride (10mmol/1) also markedly inhibited induced insulin release.
Inhibition of stimulated insulin release by trifluoperazine (3.5 and 10 ~tmol/1) is illustrated in Table 5 . With higher concentrations of this agent basal insulin release was increased: the presence of 30 ~tmol/1 caused the baseline to double. From Table  6 can be seen the effects of vinblastine (0.01 and 0.1mmol/1) and colchicine (0.1 and 1.0mmol/1). Both substances reduced stimulated insulin release. Their tendency to increase basal insulin release became significant (p < 0.05) in the presence of 0.1 mmol/1 vinblastine.
The powerful inhibitory action of adrenaline (5.0 and 10 ~tmol/1) on the responsiveness of the tumour is shown in Table 7 . Inhibition by somatostatin (1.0 and 5.0 ~tmol/1) is also shown.
Discussion
The tumour, if shown capable of the exocytosis of insulin, would provide secretory material in greater quantity than is obtainable by isolating islets; and of far higher insulin content and degree of differentiation than that from previously studied islet cell tumours [2, 9, 10] . The characteristics of insulin secretion by pancreatic B cells have been described in detail [for reviews see 3, 8] . To this extent criteria of normal insulin secretion exist that may be applied to a proposed model.
Both leucine and theophylline stimulated insulin release by the tumour. The release closely tracked square-wave pulses of either compound, and exhibited potentiation if the compounds were presented simultaneously. Stimulation by dibutyryl cyclic AMP and by glucagon, and inhibition by adrenaline, further implied adenosine 3' :5' cyclic monophosphate modulation of insulin release by the islet cell tumour [11] . Insensitivity to glucose in acute experiments may be an intrinsic characteristic of the tumour, or may reflect the study of tissue from a hypoglycaemic environment analogous to gross starvation [12, 13] . It is of interest that in some cases cells cultured for 24-48 h in medium containing 16.5 mmol/1 glucose released significantly more insulin than cells cultured in 5.5 mmol/1 glucose (Naber and Chick, unpublished observations).
This pattern of acute stimulation by leucine, glucagon and theophylline, but not by glucose, is found in fetal islet tissue [14] [15] [16] [17] . Sensitivity to glucagon, theophylline and dibutyryl cyclic AMP, but not to glucose has been reported of a hamster insulinoma [9, 10] .
The responsiveness of the tumour was further investigated using inhibitors. Insulin release in response to leucine plus theophylline was eliminated by interference with cellular oxidative phosphorylation, as is insulin secretion by islet tissue [18, 19] .
Calcium dependence was indicated by the reduced responsiveness of the tumour on lowering the external concentration of calcium ions [20] . The involvement of calcium in induced insulin release was confirmed by the inhibitory action of verapamil, whose blockade of transmembrane calcium ion movements [21, 22] and inhibition of islet insulin secretion [23] are well documented. Finally, the response of the tumour was inhibited by elevating the external concentration of Mg 2+ or by adding Co 2+ or La 3+ ions. The same manipulations of islet tissue have been shown to perturb membrane electrical activity and Ca 2+ handling, and to inhibit insulin secretion [20, [24] [25] [26] [27] .
Calmodulin is a widely distributed calcium binding protein that may mediate the effect of changes in intracellular calcium ion concentration [28, 29] . This protein has recently been identified in rat islets [30, 31] , and the calmodulin inhibitor trifluoperazine [32] found to inhibit insulin secretion [30] . A similar Induced insulin release was also inhibited by vinblastine and colchicine. While additional actions have been proposed, the disruption by these compounds of microtubules is well recognised, as is their inhibition of pancreatic islet secretion [33] [34] [35] . Their slight stimulation of basal insulin release from the tumour is unexplained, although apparently paradoxical effects of vincristine and colchicine have been described in islets [34, 35] . Finally, reduction of insulin release by the tumour in response to leucine plus theophylline was achieved using either adrenaline or somatostatin. Both agents inhibit insulin secretion by islet tissue [36] [37] [38] [39] .
In conclusion, the findings show that the islet cell tumour releases insulin in response to specific stimuli. The data further suggest that this release of insulin occurs by an exocytotic process which requires cellular energy, movement of calcium ions and the integrity of the microtubular system, and in which calmodulin and cyclic nucleotides participate. The tumour may thus possess a stimulus-secretion coupling mechanism very similar to that of pancreatic islet tissue, and therefore may be used as a largescale model of the insulin secretory process.
